




RealRate

PHARMACEUTICAL 2024

Actinium Pharmaceuticals Inc
Rank 174 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Actinium Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 27% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	78,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,494
Liabilities, Non-Current	1,553
Other Assets	2,632
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	35,019
Other Net Income	3,102
Other Revenues	81
Property and Equipment	550
Research and Development	38,670
Selling, General and Administrative Expense	13,331

Output Variable	Value in 1000 USD
Assets	81,445
Liabilities	45,066
Expenses	52,001
Revenues	81
Stockholders Equity	36,379
Net Income	-48,818
Comprehensive Net Income	-48,818
BaseVar	90,848
ECR before Limited Liability	48%
Economic Capital Ratio	187%